search
Back to results

Schumann Resonance and Insomnia

Primary Purpose

Insomnia

Status
Unknown status
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Schumann resonance sleep device
Placebo sleep device
Sponsored by
Chang Gung Memorial Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Insomnia focused on measuring Insomnia, Schumann resonance, Polysomnography

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • (1) participants are between 20 and 70 years old;
  • (2) participants must meet the DSM-5 diagnostic criteria for insomnia and have been diagnosed for more than three months;
  • (3) participants must be willing to sign an informed consent form;
  • (4) participants who took sleep aiding pills must cooperate not to change any medication and dosage during the study.

Exclusion Criteria:

  • (1) participants using pacemakers or cardiac monitors;
  • (2) participants with severe physical illness or after surgery, such as heart disease, metabolic diseases, or cancer;
  • (3) participants with severe mental disorders, such as schizophrenia, severe major depression, severe anxiety, bipolar disorder, dementia, substance use disorder; or severe neurological diseases such as a seizure, stroke or Parkinson's disease;
  • (4) participants with other serious sleep disorders, such as severe sleep obstructive apnea, severe periodic limb movement syndrome or narcolepsy;
  • (5) participants who are unable to attend regular follow-up evaluations;
  • (6) participants who are unable to keep good sleep hygiene and cannot stop using electronic products before going to bed.

Sites / Locations

  • Chang Gung Memorial Hospital, LinkouRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

SR device group

placebo device group

Arm Description

Outcomes

Primary Outcome Measures

actigraphy
Change in sleep latency (mins) based on actigraphy from before treatment to after treatment.

Secondary Outcome Measures

actigraphy-TST
Total sleep time (TST, mins) based on actigraphy from before treatment to after treatment.
actigraphy-SE
Sleep efficiency (SE, %) based on actigraphy from before treatment to after treatment.
actigraphy-WASO
Wake after sleep onset (WASO) based on actigraphy from before treatment to after treatment.
polysomnography (PSG)-SL
Change in sleep latency (SL, mins) based on PSG from before treatment to after treatment.
polysomnography (PSG)-TST
Change in total sleep time (TST, mins) based on PSG from before treatment to after treatment.
polysomnography (PSG)-SE
Change in sleep efficiency (SE, %) based on PSG from before treatment to after treatment.
polysomnography (PSG)-WASO
Change in wake after sleep onset (WASO, mins) based on PSG from before treatment to after treatment.
polysomnography (PSG)-SWS
Change in slow wave sleep (SWS, %) based on PSG from before treatment to after treatment.
polysomnography (PSG)-REM
Change in REM sleep (%) based on PSG from before treatment to after treatment.
Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire for assessing the subjective sleep quality, which consists of 19 items and can be calculated and combined into 7 clinically-derived component score (0-3), with higher scores indicating worse sleep quality.
36-Item Short-Form Health Survey (SF-36)
36-Item Short-Form Health Survey (SF-36) includes 11 major questions that evaluate eight components (0-100), with higher scores indicating better outcome.These components include physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional wellbeing, social functioning, pain, and general health.
sleep diary (sleep logs)-SL
From the diaries, an estimate was computed for an average of sleep latency (SL, mins).
sleep diary (sleep logs)-TST
From the diaries, an estimate was computed for an average of total sleep time (TST, mins).
sleep diary questionaire (sleep logs)-SE
From the diaries, an estimate was computed for an average of sleep efficiency (SE, %).

Full Information

First Posted
August 6, 2021
Last Updated
September 13, 2021
Sponsor
Chang Gung Memorial Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05053919
Brief Title
Schumann Resonance and Insomnia
Official Title
Sleep Improvement of Schumann Resonance in the Treatment of Insomnia-A Randomized and Double-blinded Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Unknown status
Study Start Date
July 27, 2021 (Actual)
Primary Completion Date
January 19, 2022 (Anticipated)
Study Completion Date
January 19, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chang Gung Memorial Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The double-blinded and randomized study evaluated the effectiveness and side effects of a novel non-invasive treatment, Schumann resonance (SR), in treating insomnia. The objective of this study is (1) to evaluate the improvement of sleep quality of patients with insomnia disorder by SR and (2) to be the basis for the future development of physical magnetic therapy.
Detailed Description
Insomnia is a common sleep disturbance that affects the health and quality of life of individuals and accounts for considerable utilization of medical resources. The prevalence of insomnia is approximately 30%; in Asia, the prevalence of insomnia is approximately 4% in Japan, 9.9% in South Korea, 10.3% in Taiwan. Based on the statistic of Taiwan BNHI office in a 2013 report, there is worth of 1.3 billion prescriptions of hypnotic drug in one year. In addition, the reimbursement expenditure pays up more than 1 billion New Taiwan Dollars (NTD) with increasing expense rate of 15% every year, showing insomnia causes great distress to Taiwanese. The characteristics of insomnia are difficulty with initiating or maintaining sleep, early morning waking, or non-restorative sleep. In DSM-5, the diagnosis of primary insomnia has been renamed insomnia disorder to avoid the differentiation between primary and secondary insomnia. The most common treatment for insomnia is pharmacological therapy with hypnotics such as a benzodiazepine, zolpidem, or zopiclone. However, treatment with hypnotics includes the risk of adverse effects, drug tolerance and dependence . Some past reports on different non-pharmacological treatment strategies, such as Cognitive-Behavioral Therapy (CBT), muscle relaxation training, stimulus control, sleep restriction, and sleep hygiene, have demonstrated the effectiveness of most of these non-pharmacological treatments. However, the poor compliance and inconvenience for CBT is always a big issue. Except the traditional treatment of insomnia, some folk therapies' clinical effect does not been confirmed, such as aromatherapy, music therapy, etc. Nowadays, due to development of technology for medical devices, some sleep devices were launched, aim to prolong the slow-wave sleep and enhances the sleeping quality. The investigational device in this study is a sleep device with SRF (Sleep Restore Frequency), the principle is to integrate the bio-energy generated Schumann resonances, native from Earth, and the shocks from the Earth's magnetic field. Through the non-contact method with bio-energy waves, SRF are coupled to the sleep center of the brain, inducing and adjusting the electrical activities of the sleep center. It prolongs the in-depth sleep and enhances the sleeping quality. The objective of this study is (1) to evaluate the improvement of sleep quality of patients with insomnia disorder by sleep device and (2) to be the basis for the future development of physical magnetic therapy. Sample Size Approximately 60 subjects who meet the inclusion and exclusion criteria will be enrolled into the trial and averagely separated two arms for statistical analysis. Statistical Analysis Efficacy evaluation statistics will be conducted with independent t-test or Fisher's exact test for testing the differences and conducted with Pearson correlation coefficient for the association between variables.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia
Keywords
Insomnia, Schumann resonance, Polysomnography

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SR device group
Arm Type
Experimental
Arm Title
placebo device group
Arm Type
Placebo Comparator
Intervention Type
Device
Intervention Name(s)
Schumann resonance sleep device
Intervention Description
A Schumann resonance sleep device would stably output the composite frequency of a "the Schumann resonance frequency (7.83 Hz) wave, theta wave, and delta wave". The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks.
Intervention Type
Device
Intervention Name(s)
Placebo sleep device
Intervention Description
A Placebo sleep device is an instrument with the same appearance and operation as the Schumann resonance sleep device, but does not output any frequency wave. The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks.
Primary Outcome Measure Information:
Title
actigraphy
Description
Change in sleep latency (mins) based on actigraphy from before treatment to after treatment.
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
actigraphy-TST
Description
Total sleep time (TST, mins) based on actigraphy from before treatment to after treatment.
Time Frame
4 weeks
Title
actigraphy-SE
Description
Sleep efficiency (SE, %) based on actigraphy from before treatment to after treatment.
Time Frame
4 weeks
Title
actigraphy-WASO
Description
Wake after sleep onset (WASO) based on actigraphy from before treatment to after treatment.
Time Frame
4 weeks
Title
polysomnography (PSG)-SL
Description
Change in sleep latency (SL, mins) based on PSG from before treatment to after treatment.
Time Frame
before and after 4 weeks using sleep device
Title
polysomnography (PSG)-TST
Description
Change in total sleep time (TST, mins) based on PSG from before treatment to after treatment.
Time Frame
before and after 4 weeks using sleep device
Title
polysomnography (PSG)-SE
Description
Change in sleep efficiency (SE, %) based on PSG from before treatment to after treatment.
Time Frame
before and after 4 weeks using sleep device
Title
polysomnography (PSG)-WASO
Description
Change in wake after sleep onset (WASO, mins) based on PSG from before treatment to after treatment.
Time Frame
before and after 4 weeks using sleep device
Title
polysomnography (PSG)-SWS
Description
Change in slow wave sleep (SWS, %) based on PSG from before treatment to after treatment.
Time Frame
before and after 4 weeks using sleep device
Title
polysomnography (PSG)-REM
Description
Change in REM sleep (%) based on PSG from before treatment to after treatment.
Time Frame
before and after 4 weeks using sleep device
Title
Pittsburgh Sleep Quality Index (PSQI)
Description
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire for assessing the subjective sleep quality, which consists of 19 items and can be calculated and combined into 7 clinically-derived component score (0-3), with higher scores indicating worse sleep quality.
Time Frame
before, after 2 weeks, and after 4 weeks using sleep device
Title
36-Item Short-Form Health Survey (SF-36)
Description
36-Item Short-Form Health Survey (SF-36) includes 11 major questions that evaluate eight components (0-100), with higher scores indicating better outcome.These components include physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional wellbeing, social functioning, pain, and general health.
Time Frame
before, after 2 weeks, and after 4 weeks using sleep device
Title
sleep diary (sleep logs)-SL
Description
From the diaries, an estimate was computed for an average of sleep latency (SL, mins).
Time Frame
before, after 2 weeks, and after 4 weeks using sleep device
Title
sleep diary (sleep logs)-TST
Description
From the diaries, an estimate was computed for an average of total sleep time (TST, mins).
Time Frame
before, after 2 weeks, and after 4 weeks using sleep device
Title
sleep diary questionaire (sleep logs)-SE
Description
From the diaries, an estimate was computed for an average of sleep efficiency (SE, %).
Time Frame
before, after 2 weeks, and after 4 weeks using sleep device
Other Pre-specified Outcome Measures:
Title
heart rate variability (HRV) device
Description
The measurement method is to stick four patches on participants body and measure the heart rhythm state for 10 minutes. An estimate was computed for LF/HF ratio.
Time Frame
before, after 2 weeks, and after 4 weeks using sleep device

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: (1) participants are between 20 and 70 years old; (2) participants must meet the DSM-5 diagnostic criteria for insomnia and have been diagnosed for more than three months; (3) participants must be willing to sign an informed consent form; (4) participants who took sleep aiding pills must cooperate not to change any medication and dosage during the study. Exclusion Criteria: (1) participants using pacemakers or cardiac monitors; (2) participants with severe physical illness or after surgery, such as heart disease, metabolic diseases, or cancer; (3) participants with severe mental disorders, such as schizophrenia, severe major depression, severe anxiety, bipolar disorder, dementia, substance use disorder; or severe neurological diseases such as a seizure, stroke or Parkinson's disease; (4) participants with other serious sleep disorders, such as severe sleep obstructive apnea, severe periodic limb movement syndrome or narcolepsy; (5) participants who are unable to attend regular follow-up evaluations; (6) participants who are unable to keep good sleep hygiene and cannot stop using electronic products before going to bed.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yu-shu Huang, MD.PhD.
Phone
886-975365659
Email
yushuhuang1212@gmail.com
Facility Information:
Facility Name
Chang Gung Memorial Hospital, Linkou
City
Taoyuan City
ZIP/Postal Code
333423
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yu-shu Huang, MD.PhD.
Phone
886-975365659
Email
yushuhuang1212@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Schumann Resonance and Insomnia

We'll reach out to this number within 24 hrs